Vassilios Myrianthopoulos

List of Publications by Year in Descending Order

43 papers	1,350 citations	19 h-index	36 g-index
48 ext. papers	1,561 ext. citations	5.5 avg, IF	4.1 L-index

#	Paper	IF	Citations
43	Novel Aryl-Substituted Pyrimidones as Inhibitors of 3-Mercaptopyruvate Sulfurtransferase with Antiproliferative Efficacy in Colon Cancer. *Journal of Medicinal Chemistry*, **2021**, 64, 6221-6240	8.3	6
42	Cockayne Syndrome Group B (CSB): The Regulatory Framework Governing the Multifunctional Protein and Its Plausible Role in Cancer. *Cells*, **2021**, 10,	7.9	3
41	Lipophilic Guanylhydrazone Analogues as Promising Trypanocidal Agents: An Extended SAR Study. *Current Pharmaceutical Design*, **2020**, 26, 838-866	3.3	2
40	Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy. *European Journal of Medicinal Chemistry*, **2019**, 176, 393-409	6.8	6
39	Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of viruses and species. *MedChemComm*, **2019**, 10, 991-1006	5	4
38	Investigating and re-evaluating the role of glycogen synthase kinase 3 beta kinase as a molecular target for cardioprotection by using novel pharmacological inhibitors. *Cardiovascular Research*, **2019**, 115, 1228-1243	9.9	17
37	Indirubin Analogues Inhibit Glycogen Synthase Kinase 3 Short and Growth. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	4
36	Senescence and senotherapeutics: a new field in cancer therapy. *Pharmacology & Therapeutics*, **2019**, 193, 31-49	13.9	83
35	Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. *Pharmacology & Therapeutics*, **2019**, 203, 107395	13.9	35
34	Immunohisto(cyto)chemistry: an old time classic tool driving modern oncological therapies. *Histology and Histopathology*, **2019**, 34, 335-352	1.4	7
33	The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies. *Cancers*, **2019**, 12,	6.6	6
32	A Novel Quantitative Method for the Detection of Lipofuscin, the Main By-Product of Cellular Senescence, in Fluids. *Methods in Molecular Biology*, **2019**, 1896, 119-138	1.4	7
31	From bench to bedside, via desktop. Recent advances in the application of cutting-edge in silico tools in the research of drugs targeting bromodomain modules. *Biochemical Pharmacology*, **2019**, 159, 40-51	6	
30	Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights. *Redox Biology*, **2018**, 16, 169-178	11.3	23
29	In Silico Screening of Compound Libraries Using a Consensus of Orthogonal Methodologies. *Methods in Molecular Biology*, **2018**, 1824, 261-277	1.4	3
28	A facile consensus ranking approach enhances virtual screening robustness and identifies a cell-active DYRK1B inhibitor. *Future Medicinal Chemistry*, **2018**, 10, 2411-2430	4.1	4
27	NmeA, a novel efflux transporter specific for nucleobases and nucleosides, contributes to metal resistance in Aspergillus nidulans. *Molecular Microbiology*, **2017**, 105, 426-439	4.1	1

26	Synthesis, Docking Study and Kinase Inhibitory Activity of a Number of New Substituted Pyrazolo[3,4-c]pyridines. *Chemical and Pharmaceutical Bulletin*, **2017**, 65, 66-81	1.9	5
25	Combined Virtual and Experimental Screening for CK1 Inhibitors Identifies a Modulator of p53 and Reveals Important Aspects of in Silico Screening Performance. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	6
24	Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer. *Pharmacological Research*, **2016**, 113, 18-37	10.2	45
23	Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation. *European Journal of Medicinal Chemistry*, **2016**, 114, 390-6	6.8	29
22	Exploring and exploiting the systemic effects of deregulated replication licensing. *Seminars in Cancer Biology*, **2016**, 37-38, 3-15	12.7	27
21	Novel indole-flutimide heterocycles with activity against influenza PA endonuclease and hepatitis C virus. *MedChemComm*, **2016**, 7, 447-456	5	17
20	Indirubins: A Potential Therapeutic Target in Multiple Myeloma. *Blood*, **2016**, 128, 3259-3259	2.2	
19	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. *Journal of Medicinal Chemistry*, **2016**, 59, 8787-8803	8.3	32
18	Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines. *Journal of Natural Products*, **2016**, 79, 2464-2471	4.9	10
17	Discovery of the glycogen phosphorylase-modulating activity of a resveratrol glucoside by using a virtual screening protocol optimized for solvation effects. *Planta Medica*, **2015**, 81, 507-16	3.1	6
16	An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3. *Parasites and Vectors*, **2014**, 7, 234	4	28
15	Impact of binding site waters on inhibitor design: contemplating a novel inverse binding mode of indirubin derivatives in DYRK kinases. *Journal of Cheminformatics*, **2014**, 6,	8.6	78
14	Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases. *ACS Medicinal Chemistry Letters*, **2013**, 4, 22-26	4.3	57
13	Modeling, substrate docking, and mutational analysis identify residues essential for the function and specificity of a eukaryotic purine-cytosine NCS1 transporter. *Journal of Biological Chemistry*, **2012**, 287, 36792-803	5.4	31
12	Identification of the substrate recognition and transport pathway in a eukaryotic member of the nucleobase-ascorbate transporter (NAT) family. *PLoS ONE*, **2012**, 7, e41939	3.7	36
11	A substrate translocation trajectory in a cytoplasm-facing topological model of the monocarboxylate/H+ symporter Jen1p. *Molecular Microbiology*, **2011**, 81, 805-17	4.1	23
10	Two new peltogynoids from Acacia nilotica Delile with kinase inhibitory activity. *Planta Medica*, **2010**, 76, 458-60	3.1	27
9	Design and synthesis of new C-nucleosides as potential adenosine deaminase inhibitors. *Tetrahedron*, **2010**, 66, 9620-9628	2.4	14

8	6-Br-5methylindirubin-3$oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. *International Journal for Parasitology*, **2009**, 39, 1289-303	4.3	61
7	Synthesis of 1,2-annulated adamantane heterocycles: structural determination studies of a bioactive cyclic sulfite. *Tetrahedron Letters*, **2009**, 50, 2671-2675	2	9
6	Sesquiterpene lactones from Staehelina fruticosa. *Journal of Natural Products*, **2008**, 71, 847-51	4.9	10
5	Soluble 3$6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. *Journal of Medicinal Chemistry*, **2008**, 51, 6421-31	8.3	98
4	Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. *Journal of Medicinal Chemistry*, **2008**, 51, 5229-42	8.3	108
3	An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. *Journal of Medicinal Chemistry*, **2007**, 50, 4027-37	8.3	55
2	Chemical Composition Of The Essential Oil Of Cionura Erecta (Asclepiadaceae) Inforescences. *Journal of Essential Oil Research*, **2007**, 19, 266-268	2.3	1
1	Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. *Journal of Medicinal Chemistry*, **2004**, 47, 935-46	8.3	308